Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Lucid Diagnostics, Inc. (LUCD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$0.45+8.83%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LUCD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Sufficient capital to fund growth | A supporting condition in Lucid Diagnostics, Inc.'s published investment case. The stated target is Maintain capital to fund operations through FY27. | Improving | Capital runs low forcing dilutive financing or operational cutbacks | $15M raised vs FY27 runway target LUCD raised $15M in Series C preferred stock to fund operations. Nasdaq issued delisting notice due to sub-$1 stock price. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making commercialization story, not an established durable compounder. The long-term thesis is in a watch state: revenue has improved, but operating losses remain large and recent performance is below its industry cohort.
LUCD is valued at a premium to peers, while the valuation model has low confidence and points to optionality, meaning value depends on future opportunities that are not yet proven. The expectations gap is slightly negative, so expectations appear a little ahead of the evidence; the valuation is expensive, though the snapshot does not flag the full combination of expensive, weak, and turbulent conditions.
Near term, revenue rose from $1.256 million in the first quarter of 2026 to $1.474 million in the second, but operating losses remained around $12 million in both quarters. Management has reported progress on Medicare payment and coding pathways and adoption of a commercial coverage policy by multiple health plans, but the California claims pathway is still unresolved. Near-term execution risk is elevated, with a 58% estimated miss probability and a run of consecutive earnings misses.
The multi-year case hinges on whether EsoGuard coverage and payment progress leads to broader access, sustained revenue growth, and narrower operating losses. A guidance cut or further weakening in jobs could weigh on the business outlook, while continued strong results and higher guidance from healthcare bellwethers could support sector conditions.
Over the next one to three years, LUCD remains an early commercialization thesis with meaningful execution and loss risks, alongside signs of progress in coverage and revenue. The evidence is mixed, and the case depends on converting those milestones into improved operating results. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Lucid Diagnostics, Inc.'s published investment case. The stated target is EPS loss improves to >= -$0.17 in FY27. |
| Improving |
| EPS loss worsens or fails to improve beyond -$0.24 in FY26 and -$0.17 in FY27 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to support turnaround | A primary condition in Lucid Diagnostics, Inc.'s published investment case. The stated target is >= $7.4M revenue in FY26 and >= $20.1M in FY27. | Broken | revenue falls below $7.4M in FY26 or fails to grow toward $20.1M in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “|| ● | Processed 2,770 EsoGuard ® Esophageal DNA Tests in 2Q26.” “Highlights from the first quarter and recent weeks : ● Processed 3,177 EsoGuard ® Esophageal DNA Tests in 1Q26.” Revenue was $1.474 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.17 → $-0.18 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-07-25 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-07-26 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-07-27 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-07-28 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-07-29 | $-0.17 | $20,113,200 | 4 / 5 |
| 2026-07-30 | $-0.17 | $20,113,200 | 4 / 5 |
| 2026-07-31 | $-0.17 | $20,113,200 | 4 / 5 |
| 2026-08-01 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-02 | $-0.17 | $20,113,200 | 4 / 5 |
| 2026-08-03 | $-0.17 | $20,113,200 | 4 / 5 |
| 2026-08-04 | $-0.17 | $20,113,200 | 4 / 5 |
| 2026-08-05 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-06 | $-0.17 | $20,113,200 | 4 / 5 |
| 2026-08-07 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-08 | $-0.17 | $20,113,200 | 4 / 5 |
| 2026-08-09 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-10 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-12 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-13 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-14 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-15 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-16 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-17 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-18 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-19 | $-0.17 | $20,153,200 | 3 / 3 |
| 2026-08-20 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-08-21 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-08-22 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-08-23 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-08-24 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-08-25 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-08-26 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-08-27 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-08-28 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-08-29 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-08-30 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-08-31 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-01 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-02 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-03 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-04 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-05 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-06 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-07 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-08 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-09 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-10 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-11 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-12 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-13 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-14 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-15 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-16 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-17 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-18 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-19 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-20 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-21 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-22 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-23 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-24 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-25 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-26 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-27 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-28 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-29 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-09-30 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-10-01 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-10-02 | $-0.18 | $16,707,306 | 3 / 3 |
| 2026-10-03 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-04 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-05 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-06 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-07 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-08 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-09 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-10 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-11 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-12 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-13 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-14 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-15 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-16 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-17 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-18 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-19 | $-0.18 | $16,713,125 | 3 / 3 |
| 2026-10-20 | $-0.18 | $16,759,020 | 3 / 3 |
| 2026-10-21 | $-0.18 | $16,759,020 | 3 / 3 |
| 2026-10-22 | $-0.18 | $16,759,020 | 3 / 3 |
| 2026-10-23 | $-0.18 | $16,759,020 | 3 / 3 |
| 2026-10-24 | $-0.18 | $16,713,339 | 3 / 3 |
| 2026-10-25 | $-0.18 | $16,713,339 | 3 / 3 |
| 2026-10-26 | $-0.18 | $16,713,339 | 3 / 3 |
| 2026-10-27 | $-0.18 | $16,713,339 | 3 / 3 |
| 2026-10-28 | $-0.18 | $16,713,339 | 3 / 3 |
| 2026-10-29 | $-0.18 | $16,713,339 | 3 / 3 |
| 2026-10-30 | $-0.18 | $16,713,339 | 3 / 3 |
| 2026-10-31 | $-0.18 | $16,713,339 | 3 / 3 |
| 2026-11-01 | $-0.18 | $16,713,339 | 3 / 3 |
| 2026-11-02 | $-0.18 | $16,713,339 | 3 / 3 |
| 2026-11-03 | $-0.18 | $16,713,339 | 3 / 3 |
| 2026-11-04 | $-0.18 | $16,713,339 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.